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Histone lysine methylation has been identiﬁed as an important
epigenetic marker. Methylation of speciﬁc lysine residues in the
histone tails can act as either activators or repressors of DNA tran-
scription and thus has a key role in the regulation of speciﬁc genes
[1]. Histone–lysine demethylase (HDM) enzymes have an impor-
tant role in maintaining the correct transcription levels and conse-
quently, they are central in epigenetic research. One class of HDMs
are the Jumonji-C-Domain (JmjC) containing HDMs that are 2-oxo-
glutarate (2OG) and Fe dependent enzymes belonging to the 2OG
dependent oxygenase super family [2].
The HDM KDM4C (GASC1/JMJD2C) has been identiﬁed as a
putative oncogene as it is upregulated in different types of cancer
[3], and inhibition of this enzyme has been shown to arrest tumor
cell proliferation [4]. The HDM KDM6A (UTX) has been identiﬁed
as a regulator of HOX genes that are imperative during cellular dif-
ferentiation [5]. Further work has shown that KDM6A most likelychemical Societies. Published by E
ic core of KDM4C; ccKDM6A,
e di-carboxylic acid; 2OG,
t assay; FDH, formaldehyde
ne lysine demethylase; HRP,
alylglycineacts as a tumor repressor [6]. Thus, an inhibitor should be selective
for KDM4C over KDM6A.
Mutations in the PHF8 HDM impairing its catalytic activity have
been shown in X-linked mental retardation patients [7] and
recently, overexpression of PHF8 was shown in prostate cancer
cells [8]. Thus, depending on the context of expression pattern,
PHF8 is another member of the JmjC HDM family towards which,
inhibitors targeting the putative oncogenes should be selective.
The three enzymes are active towards different methylation states,
with KDM4C primarily demethylating trimethylated lysine 9 on
histone 3 (H3K9me3), KDM6A demethylating H3K27me3 and
PHF8 demethylating H3K9me2.
A number of HDM inhibitors have been reported [9], including
N-oxalyl-glycine (NOG) based derivatives with increased afﬁnity
and selectivity [10], inhibitors that are based on 2,4-pyridine
di-carboxylic acid (2,4-PDCA) [11], hydroxamic acids [12,13], and
recently, a KDM4C selective substrate-based inhibitor [14]. In addi-
tion to the reported synthesis of de-novo compounds, screening of
a number of different compound libraries against KDM4E have
been reported [15–17]. Whereas most screening studies have been
focused on identiﬁcation of small molecule inhibitors of a single
HDM, a recent paper demonstrates that selectivity can indeed be
obtained, as 2,4-PDCA was shown to have signiﬁcant selectivity
for KDM4C over KDM6A [18].
In this study, a 640 member diversity-optimized natural prod-
uct library was screened for inhibitors of KDM4C. Based on one
of the hits, a subset of compounds were selected and screenedlsevier B.V. All rights reserved.
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in inhibitor selectivity between closely related HDM enzymes, fol-
lowed by in-cell evaluation of a selected hit.
2. Materials and methods
2.1. Reagents and chemicals
All chemicals used for buffers, co-factors, lysozyme, DNAse,
formaldehyde dehydrogenase from Pseudomonas putida, N-oxalyl-
glycine, 2,4-pyridine di-carboxylic acid, TMB Elisa detection solu-
tion, BSA, Tween-20, a-cyano-4-hydroxy cinnamic acid and
Hoechst staining (bisBenzimide H 33342), were obtained from Sig-
ma-Aldrich, Denmark. Solvents for MALDI-TOF were of HPLC-grade
and from Merck, Denmark. EDTA free protease inhibitor cocktail
tablets used in protein puriﬁcation and FuGENE HD for transfection
were from Roche. Histone tail fragments Biotin-H3(1-24)K9me3,
H3(7-14)K9me3, H3(1-24)K4me3K9me2 and H3K27me3 synthetic
peptide substrates were purchased from Peptide 2.0, USA or gener-
ously donated by Novo Nordisk A/S, Denmark. Reacti-bind strepta-
vidin functionalized 96-well plates were from Pierce, rabbit anti-
mouse-HRP conjugate was purchased from DAKO and anti-
H3K9me2 mouse antibody as well as primary antibodies for cell
based assays; rabbit polyclonal anti-H3K9me3 (ab8898) and rabbit
polyclonal anti-H3K9me1 (ab9045), were from Abcam. The 640
compound Natural Product Library was purchased from TimTec.
The plasmid pET His KDM4C1-349 for recombinant expression of
the His-tagged catalytic core of human KDM4C (cc-KDM4C, 1-
349) and pCMV-HA-KDM4C for ectopic expression of HA-tagged
full-length human KDM4C [4] were generously donated by the Bio-
tech Research and Innovation Centre (BRIC), Denmark. The pOPIN
vector J was a gift from the Oxford Protein Production Facility,
Great Britain. Compounds 1–9, 11–13 were purchased from Tim-
Tec, while compounds 10, 14–18 were donated by Novo-Nordisk
A/S. Dulbecco’s Modiﬁed Eagle Medium (DMEM) and secondary
antibodies for cells based assays, Alexa Flour488 anti-mouse
and Alexa Flour594 anti-rabbit was purchased from Invitrogen.
Puriﬁed mouse monoclonal anti-HA.11 (Clone 16B12) was pur-
chased from Covance – Biosite, Sweden.
2.2. Screening of natural product library applying the ELISA assay
Streptavidin plates were washed with buffer A (50 mM Hepes,
50 mM NaCl pH 7.4) and biotinylated peptide (10 lg/ml) was
immobilized over night at 4 C. The following morning the plate
was washed and blocked for 2 h at r.t. with buffer B (50 mMHEPES,
50 mM NaCl, 0.05% Tween-20 and 0.1% BSA pH 7.4). In a separate
96-well plate, the catalytic core of KDM4C (ccKDM4C) was diluted
to 250 nM in reaction buffer (ﬁnal volume 100 ll) and 5 ll (1 mg/
ml) of the putative inhibitors were added to the appropriate wells.
Four wells were used as a negative control without enzyme and
four wells were used as a positive control with 5% DMSO. The con-
trols were used for calculating Z’-values for each of the eight
screened plates (see Supplementary data). The plate was incubated
on ice for 1 h. The blocked functionalized plate was washed with
buffer A and 100 ll enzyme/inhibitor mixture was added to each
well and the plate was incubated for 1.5 h at r.t. followed by wash
with buffer A. The primary anti-H3K9me2 antibody was diluted
1:1000 into buffer B, added to the plate and incubated for 1 h at
r.t. The plate was washed with buffer A and the secondary antibody
was added as described for the primary antibody and incubated for
1 h at r.t. Following the second incubation, the plate was thor-
oughly washed with buffer A and 100 ll of tetra-methylbenzidine
solution (Sigma) was added to each well until a desired color inten-
sity was obtained. The reaction was quenched by addition of 50 ll1 M HCl to each well and the absorbance was recorded at 450 nM
on a Saﬁre microplate-reader (Tecan).
2.3. FDH assay
The FDH assays were carried out essentially as described
elsewhere [19], for details see Supplementary data.
2.4. Cell based assay
Human U2-OS osteosarcoma cells were cultured in monolayer
in Dulbecco’s Modiﬁed Eagle Medium (DMEM) supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin (DMEM/FB
S/PS). 1  103 U2-OS cells were seeded in 100 lL in each well of a
96 well NUNC ﬂat bottomed transparent plate 12 h before transfec-
tion. Transfection was performed using FuGENE HD according to
the manufacturer’s instructions.
Compound 10 was dissolved to 250 mM in 1 M sterile Tris–HCl
pH 9.0 and a twofold dilution series was prepared freshly for each
individual experiment. 5 lL from the dilution series was mixed
with 95 lL DMEM/FBS/PS and themedia was exchanged. Cells were
incubated for 23 h and ﬁxed with 4% paraformaldehyde in Phos-
phate Buffered Saline (PBS), permeabilished with 0.1% Triton X100
in PBS and blocked for 1 h in DMEM/FBS/PS. Cells were stained with
mouse anti-HA.11 antibody for detection of transfected cells, and
either rabbit anti-H3K9me3 antibody or rabbit anti-H3K9me1 anti-
body for detection of H3K9 methylation level over night at 4 C.
Cells were washed with PBS and stained with Hoecst for nuclei
detection and secondary antibodies, Alexa Flour488 anti-mouse
and Alexa Flour594 anti-rabbit at 4 C in the dark. Cells were
washed with PBS and left at 4 C in PBS before imaging. The cells
were imaged on an IN Cell Analyzer 1000 (GE Healthcare), and 6
images per well were acquired using a 10 objective to count
2000 cells per well.
Acquired images were analyzed using the IN Cell Analyzer
Workstation 3.6 software (GE Healthcare). Average intensity/nu-
clei for each methyl mark were normalized against non-transfec-
ted cells and transfected cells above (for H3K9me1 staining) and
below (for H3K9me3 staining) this threshold were counted and
plotted as percentage of the total number of transfected cells. For
each concentration of inhibitor, the intensity was measured on
an average of 350–750 transfected cells. Each experiment was per-
formed in triplicate on three different days.
Preparation of cover slips was performed essentially as
described above. The stained cover slips were washed one time
in de-mineralized water and dried over night in the dark. The cover
slips were mounted on glass slides and sealed with transparent
nail polish. The cover slips were analyzed with a Carl Zeiss confocal
microscope and LSM 5.1 software 3.3. Results and discussion
3.1. Screening of natural product library for inhibitors of ccKDM4C.
Using a 24-meric N-terminally biotinylated H3K9me3 peptide,
an ELISA-based assay was developed, where the product formation
was detected using a monoclonal antibody directed against the
di-methylated product. Product formation was detected using a
Horse Radish Peroxidase (HRP) conjugated secondary antibody. A
test of the assay revealed that Z’-values [20] >0.5 could be obtained
with the described setup and the assay was validated against the
known KDM4C inhibitor 2,4-PDCA (Fig. S4). The assay was con-
ducted at 250 nM ccKDM4C, which is 10-fold lower compared to
the in-house FDH assay setup.
Fig. 1. The inhibition of KDM4C by 1 determined using FDH assay and veriﬁed by
MALDI-TOF-MS. (A) Inhibition curve of 1 against KDM4C at 25 lMH3(7-14)K9me3,
showing an IC50 of 13.7 lM. Inset shows the structure of compound 1. (B) MALDI-
TOF mass spectrum of a reaction-mixture consisting of KDM4C and 25 lM
H3(7-14)K9me3 (m/z = 846) without inhibitor. The spectrum shows formation of
H3(7-14)K9me2 (m/z = 832). (C)MALDI-TOFmass spectrumwith amixture identical
to that in panel B, but with 50 lM 1 added, showing that the inhibitor arrests the
product formation. The peak at m/z = 840 results from sample contamination.
Fig. 2. Analysis of the mechanism of action of 10. Top panel (A and B) Vmax and KM
values for ﬁxed 2OG concentrations and varying H3(7-14)K9me3 concentrations at
0 lM 10, 15.6 lM 10, 31.25 lM 10 and 62.5 lM 10. Bottom panel (C and D) Vmax
and Km values for ﬁxed H3(7-14)K9me3 concentrations and varying 2OG concen-
trations at 0 lM 10, 15.6 lM 10 and 31.25 lM 10. Full Michaelis–Menten curves are
found in Supplementary data.
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ccKDM4C in a commercially available diversity optimized natural-
products library containing 640 compounds. A number of hits in
the library were identiﬁed (see Fig. S5 and Table S1), and based
on structural features, a subset of 21 compounds were subse-
quently tested in the standard FDH coupled assay (Table S1). This
approach identiﬁed compound 1 as an inhibitor of ccKDM4C with
an IC50 of 13.7 lM (Fig. 1).Table 1
Inhibition by catechol containing compounds from analysis of the 18 compounds selected
KDM4C PHF
Single point inhibition* IC50/Fe2+ ratioa Sing
1 + 13.7 ± 1.3/2.8 –
2 + 90 ± 1.4/1.5 –
6 + 64.6 ± 1.4/>6 –
10 + 52 ± 1.4/2.5 –
NI: No inhibition.
a The ratio between IC50 values determined at 100 lM and 20 lM Fe2+, respectively.
* Classiﬁcation of the compound as an inhibitor based on screening at a single high inh3.2. Structurally similar compounds to compound 1 tested against
other HDMs.
A second set consisting of 18 compounds, selected based on
their structural similarity to 1 (cf Table 1 and Table S2), was tested
against three different JmjC HDM catalytic cores, namely
ccKDM4C, ccKDM6A, and a truncated version of PHF8 (tPHF8),
comprising the PHD domain and the catalytic core, (see
Supplementary data). The enzymes were selected as representa-based on their similarity to compound 1.
-8 KMD6A
le point inhibition* IC50/Fe2+ ratioa Single point inhibition* IC50/Fe2+ ratioa
NI + 5.5 ± 1.1
NI + 7.2 ± 1.2
NI + 20 ± 1.4
NI + 12 ± 1.2
ibitor concentration as shown in Fig. S6.
Fig. 3. Cell-based activity of compound 10 in U2-OS cells. (A) Percentage of KDM4C
transfected U2-OS cells at different concentrations of 10 with H3K9me3 levels at
the threshold value. The threshold value for the H3K9me3 signal is calculated as the
average intensity/nuclei of non transfected cells, and represent the base level of
H3K9me3 in the U2-OS cells. At increasing concentrations of 10, the percentage of
KDM4C transfected cells with H3K9me3 signals at the base level of H3K9me3
increases, indicating in cell inhibition of KDM4C. (B) U2-OS cells transfected with
HA-tagged KDM4C in the abscence or presence of 2.5 mM 10. White arrows indicate
cells with changed H3K9me3 levels.
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ing selective inhibitors for different HDM subfamilies. Initially,
the 18 selected compounds were screened against the enzyme
ensemble at a single concentration of 250 lM in the FDH assay
(see Fig. S6). IC50 curves were subsequently determined for
compounds that exhibited inhibition in the single-point
determinations.
In this second set of compounds, compounds 2, 6 and 10 were
identiﬁed as inhibitors of ccKDM4C and ccKDM6A (Table 1), while
interestingly; none of the compounds affected the activity of
tPHF8. However, the IC50 value of compound 6 in the inhibition
of ccKDM4C turned out to be dependent on the Fe2+ concentration.
Thus, it is likely the inhibitor chelates Fe2+ and thereby inhibits the
protein in an unspeciﬁc manner (Table 1). The compounds had
higher afﬁnity for ccKDM6A, indicating that these homologous
enzymes are sufﬁciently different to achieve selectivity using the
compounds identiﬁed in this screen as leads. It is of particular
interest that compound 2 is approximately 10-fold less potent to-
wards ccKDM4C compared to 1, while both compounds were
equally potent towards ccKDM6A. This is also true for 10, which
was less potent towards both enzymes, but at the same time, the
smaller molecule is more suited for engineering in order to achieve
selectivity.3.3. Mode of action of compound 10
Catechols are known inhibitors of 2OG dependent enzymes, and
as highlighted in a recent review, the inhibition mechanism of this
compound class has been shown to be complex [21]. It is, however,
interesting that no inhibition of PHF8 was observed, indicating that
inhibition by catechols does not occur through an unspeciﬁc mode
of action. To ensure that the absence of inhibition against PHF8
was not a defect of the FDH assay, the activity of PHF8 was assayed
in the presence of two known HDM inhibitors (NOG and 2,4-PDCA)
and for both compounds a decreased enzyme activity was ob-
served, thereby conﬁrming the validity of the assay (Fig. S7).
An analysis of the mechanism of inhibition of 10 showed
mixed-mode inhibition with respect to the peptide substrate
(Fig. 2), as increasing inhibitor concentrations resulted in decreas-
ing KM values and simultaneously decreasing kcat values. Mean-
while, the inhibitor exhibited non-competitive inhibition with
respect to the 2OG cofactor as the effect of the inhibitor was solely
to cause a lowering of kcat. This demonstrates that 10may not bind
in the cofactor pocket, but could interact with the peptide sub-
strate, either directly or indirectly.
3.4. In-cell inhibition of KDM4C by compound 10
To evaluate the compounds in a cellular setting, the effect of 10
on the methylation level of chromatin in U2-OS cells transfected
with HA-tagged full length KDM4C was studied. For reference,
the known KDM4C inhibitor, 2,4-PDCA, was used to validate the
assay (data not shown). 2,4-PDCA and 10 have LogP values in a
similar range (0.59 and 0.88, respectively), and their bioavailabili-
ties were assumed to be in a similar range as well. The compounds
were shown to prevent a decrease in the H3K9 trimethylation level
in cells transfected with KDM4C, as compared to untreated KDM4C
transfected U2-OS cells (Fig. 3A and Fig. S9). This observation was
conﬁrmed by microscopy on immuno-stained cells (Fig. 3B and
Fig. S9). Similarly, examination of the level of H3K9 mono-methyl-
ation showed that the compounds prevented an increase in signal
intensity of KDM4C transfected cells treated with 2,4-PDCA and 10.
The methylation level in un-transfected cells remained unchanged
with increasing concentrations of 2,4-PDCA and 10 (Fig S10). These
results demonstrate that the identiﬁed compound 10 is indeed a
relevant HDM inhibitor with in cell inhibitory effects on KDM4C.
The identiﬁed compounds have previously been associated with
inhibitory effects in other cancer related studies. Compound 1,
commonly known as caffeic acid, is a known anti-oxidant, which
has been shown to inhibit DNAmethylation as well as growth of li-
ver metastasis, possibly through inhibition of matrix-metallopro-
teases [22,23] 10 has previously been shown to inhibit cancer cell
proliferation through oxidative processes [24,25]. The ﬁndings
reported here indicate that the mechanism of action of the two
compounds is even more complicated than initially believed, since
the compounds appear to also function on the level of chromatin
methylation.
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